| Detailed information |
|---|
| CancerLivER ID | 2531 |
| Biomarker | TRIM25, EIF2S3, CLECSF14, DXYS155E, T-cell receptor beta locus, GIF2H2, SPON2, VDAC2, SLC15A3, HBP1, PTPRC, FES, CDC5L, ITGB2, MPP1, NDUFA2, AHCYL1, CNP, SQLE, RPA3, LGALS1, HLA-DQA1 , STMN1, PCOLCE, LOC387680, DPT, SLK, IGBP1, SNRPG, Human-alpha1-antitrypsin gene (S variant) complete cds, SIAHBP1, |
| Biomarker Name/Symbol (given in Publication) | TRIM25, EIF2S3, CLECSF14, DXYS155E, T-cell receptor beta locus, GIF2H2, SPON2, VDAC2, SLC15A3, HBP1, PTPRC, FES, CDC5L, ITGB2, MPP1, NDUFA2, AHCYL1, CNP, SQLE, RPA3, LGALS1, HLA-DQA1 , STMN1, PCOLCE, LOC387680, DPT, SLK, IGBP1, SNRPG, Human-alpha1-antitrypsin gene (S variant) complete cds, SIAHBP1, SLC12A7, LITAF, CYP1A2, SRPX, MNDA |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Multicentric occurrence-associated genes and the multicentric recurrence-associated genes; but not validated on independent daatset |
| Experimental Condition | Single nodular HCC group v/s multicentric HCC group; associated with multicentric recurrence |
| Cancer type | Hepatocellular carcinoma |
| Regulation | 7 genes Downregulated i.e. CYP1A2, Human-alpha1-antitrypsin gene (S variant) complete cds, PCOLCE, CNP, DXYS155E, CLECSF14, TRIM25 and 29 get upregulated in |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 16788756 |
| Type of Biomarker | Diagnostic and prognostic |
| Pathway | Transport |
| Cohort | 40 patients with hepatitis C virus-positive hepatocellular carcinoma (HCC): classified into 4 groups: group A, patients belonging to the SN group with no evidence of recurrence in the liver remnant (n = 21); group B, patients in the SN group with multicentric recurrence (n = 7); group C, patients in |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Single nodular HCC group v/s multicentric HCC group |
| Year of Publication | 2006 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |